Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-08-16
2011-08-16
Mertz, Prema (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000
Reexamination Certificate
active
07998686
ABSTRACT:
Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.
REFERENCES:
patent: 5424221 (1995-06-01), Westermark et al.
patent: 5639617 (1997-06-01), Bohuon
patent: 7361473 (2008-04-01), Valkirs et al.
patent: 0 115 459 (1984-08-01), None
patent: WO-94 04927 (1994-03-01), None
Okahara, S., et al., “Serum Pro-Gastrin-Releasing Peptide (PROGRP) in Subjects With or Without Hericibacter Pyloriinfection”, Gastroenterology, U.S. Elsevier, New York, NY, vol. 110, No. 4, Apr. 1996, pp. A217 XP000884904, ISSN: 0016-5085, abstract.
Noriharu, S., et al., “Elevated Progastrin-Releasing Peptide (31-98) Concentrations in Pleural Effusions Due to Small-Cell Lung Carcinoma”, Respiration, CH, Karger, Basel, vol. 63, No. 2, Mar. 1, 1996, pp. 106-110, XP000608937, ISSN: 0025-7931, pp. 107, col. 1, paragraphs 2, 4; p. 107, col. 2, paragraph 4, figure 1; p. 109, col. 2, paragraphs 2, 3.
Miyake, Y., et al., “Pro-Gastrin-Releasing Peptide (31-98 is a Specific Tumor Marker in Patients With Small Cell Lung Carcinoma”, Cancer Research, vol. 54, Apr. 15, 1994, pp. 2136-2140, XP002132024, p. 2137, col. 1, line 1-line 7, figure 2.
Guo, Y., et al., “Production of Endothelins by the Ventilatory Muscles in Septic Shock”, American Journal of Respiratory Cell and Molecular Biology, US, American Lung Assocation, New York, NY, vol. 1, No. 3, Sep. 1998, pp. 470-476, XP000879419 ISSN: 1044-1549, pp. 472, col. 2, paragraph 3.
McLoughlin, L., et al., “Characterization of Circulating Pro-opiomelancocortin-Related Peptides in Human Septic Shock”, Journal of Endocrinology, GB, Bristol, vol. 119, No. 1, Oct. 1988, pp. 159-165, XP000879345, ISSN: 0022-0795 cited in the application, abstract, pp. 161, col. 1, paragraph 2.
Nylen, E.S., et al, “Pneumonitis-Associated Hyperprocalcitoninemia”, American Journal of Medical Sciences, XX, XX, vol. 312, No. 1, Jul. 1996, pp. 12-18, XP000879269, pp. , ISSN: 0002-9629, 15, col. 1, line 2-line 5, p. 15, col. 2, line 5-line 9.
Assicot, M. , et al., “High Serum Procalcitonin Concentrations in Patients With Sepsis and Infections”, The Lancet, GB, Lancet Limited, London, vol. 341, No. 8844, Feb. 27, 1993, pp. 515-518, XP000371780, ISSN: 0140-6736, abstract.
Karzai W., et al., “Procalcitonin—A New Indicator of the Systemic Response to Severe Infections”, Infection, DE, MMV Medizin Verlag, Muenchen, vol. 25, No. 6, Nov. 1997, pp. 329-334, XP000879253, ISSN: 0300-8126, pp. 329, col. 2, paragraph 2.
Qureshi, N.U., et al., “Endogenous Neuropeptide Y Mediates Vasoconstriction During Endotoxic and Hermorragic Shock”, Regulatory Peptides. vol. 75-76, Sep. 25, 1998, pp. 215-220, XP000925467—abstract, pp. 215, col. 1-col. 2, line 3, p. 219, col. 1, paragraph 3.
Norlander. T., et al., “Effects of Experimental Mycoplasma Pulmonis Infection on Sensory Neuropeptides and Airway Mucosa in the Rat”, European Respiratory Journal, vol. 10, 1997, pp. 2334-2342, XP000925422, abstract, p. 2341, col. 1, paragraph 2.
Kullertz, G. “Die Bedeutung Der Aktivitatsbestimmung Des Enzyms Dipeptidyl-Peptidase IV (DP IV) Im Klinischen Laboratorium”, Lab Med., vol. 12, 1998, pp. 123-130, XP000933866, pp. 123, col. 1-p. 124, col. 1, paragraph 1, p. 125, col. 1, paragraph 2-paragraph 3, table 4, p. 128, col. 1, paragraph 2, p. 129, col. 1, paragraph 4-paragraph 5.
Vanham, G., et al., “Decreased Expression of the Memory Marker CD26 on Both CD4 + CD8 + T Lymphocytes of HIV-Infected Subjects”, Journal of Acquired Immune Deficiency Syndromes, vol. 6, No, 7, Jul. 1993, pp. 749-757, XP000925435, p. 751, col. 1, paragraph 6, p. 753, col. 2, paragraph 3, p. 756, col. 1, paragraph 2.
Yaron, A., et al., “Proline-Dependent Structural and Biological Properties of Peptides and Proteins”, Critical Reviews in Biochemistry and Molecular Biology, vol. 28, 1993, pp. 31-81, XP000925565, p. 55, col. 1, line 15—col. 2, p. 56, col. 2, paragraph 2—p. 57, col. 1, line 3.
Oravecz, T., et al., “Regulation of the Receptor Specificity and Function of the Chemokine Rantes (Regulated on Activation, Normal T Cell Expressed and Secreted) by Dipeptidyl Peptidase IV (CD26)-Mediated Cleavage”, Journal of Experimental Medicine, JP, Tokyo, vol. 186, No. 11, Dec. 1, 1997, pp. 1865-1872, XP002056059, ISSN: 0022-1007 cited in the application, the whole document.
Proust, P., et al., “Amino-Terminal Truncation of Chemokines by CD26/Dipeptidyl-Peptidase IV”, Journal of Biological Chemistry, US, American Society of Biological Chemists, Baltimore, MD. vol, 273, No. 13, Mar. 27, 1998, pp. 7222-7227-7227, XP002102982 ISSN: 0021-9258 cited in the application, the whole document.
Wrenger, S., et al., “Amino-Terminal Truncation of Procalcitonin, a Marker for Systemic Bacterial Infections, by Dipeptidyl Peptidase IV (DP IV)”, FEBS Letters (Jan. 21, 2000), vol. 466, No. 1, pp. 155-159, XP002143500, the whole document.
Nylen, E.S., et al., “Mortality Is Increased by Procalcitonin and Decreased by an Antiserum Reactive to Procalcitonin in Experimental Sepsis”, Crit. Care Med., 1998, vol. 26, No. 6, pp. 1001-1006.
Coillie, E.V., et al., “Functional Camparison of Two Human Monocyte Chemotactic Protein-2 Isoforms, Role of the Amino-Terminal Pyroglutamic Acid and Processing by CD26/Dipeptidyl Peptidase IV”, Biochemistry 1998, 37, pp. 12672-12680, Published on Web Aug. 18, 1998.
Prow and Iwhlda present the GUIDE on : DC 26 Author : Martin Hegen, Reviewer: Tamas Oraveez, 4 pages.
Stieber, P., et al., Pro-Gastrin-Releasing Peptide (PROGRO)—A New Marker in Small-Cell Lung Carcinomas, J. Lab Med. 1997, 21(6), pp. 336-344.
In Vitro Test for Determination of Pro-Gastrin-Releasing Peptide (PROGRP) in Serum by EIA, PROGRP Elisa Kit, 5 pages.
Richards, A. M., et al., “Plasma N-Terminal Pro-Brain Natriuretic Peptide and Adrenomedullin: New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction,” Circulation—Journal of the American Heart Association, 1998; 97; 1921-1929—Downloaded from circ.ahajournals.org on Jan. 19, 2010.
Qi, Y. F., et al., “Effects of Different Peptide Fragments Derived from Proadrenomedullin on Gene Expression of Adrenomedullin Gene,” Peptides 23 (2002) 1141-1147.
Balci, C. et al., “Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit,” Critical Care, 2003, vol. 7, pp. 85-90.
Bergmann, Lebenslauf—Dr. Andreas Bergmann, 2009.
Bone, R. C. et al., “Definitions for sepsis and organ failure and guidelines for the use of innovation therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine,” Chest, 1992, vol. 101, pp. 1644-1655.
Brandt, I. et al., “Dipeptidyl-peptidase IV Converts Intact B-Type Natriuretic Peptide into Its des-SerPro Form,” Clinical Chemistry, 2006, vol. 52, No. 1, pp. 82-87.
Brazeau, P. et al., “High biological activity of the synthetic replicates of somatostatin-28 and somatostatin-25,” Regulatory Peptides, Jan. 1981, vol. 1, No. 4, pp. 255-264.
Christ-Crain, M. et al., “Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study,” Critical Care, 2005, vol. 9, No. 6, R816-824.
Docherty, K. et al., “Post-Translational Proteolysis in Polypeptide Hormone Biosyntheis,” Annual Review of Physiology, Mar. 1982, vol. 44, pp. 625-638.
Duckworth, W. C. et al., “Conversion of biosynthetic human proinsulin to partially cleaved intermediates by collagenase proteinases adsorbed to isolated rat adipocytes,” Biochem, J., 1988, vol. 255, pp. 277-284.
Eberlein, G, A. et al., “Patterns of Prohormone Processing,&#
Bergmann Andreas
Struck Joachim
Weglöhner Wolfgang
B.R.A.H.M.S. GmbH
Mertz Prema
Millen White Zelano & Branigan P.C.
LandOfFree
Method for determining sepsis using pro-BNP does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for determining sepsis using pro-BNP, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for determining sepsis using pro-BNP will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2672822